Second-line treatment options for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two different drug combinations for people with advanced colorectal cancer that has grown after first treatment. It tests whether a newer drug (fruquintinib) combined with standard chemotherapy works as well as the current standard (bevacizumab) combined with chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have metastatic colorectal cancer that has progressed after first-line treatment.
- You have not had more than one prior systemic therapy.
- Your cancer is not BRAF V600E mutated and is not MSI-high/dMMR.
- You have adequate liver, kidney, and blood function.
- You have not had certain heart problems, strokes, or blood clots recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
This trial compares two different drug combinations for people with colorectal cancer that has spread and has already been through one round of chemotherapy. One combination uses a newer targeted pill (fruquintinib) while the other uses a standard targeted medicine (bevacizumab), both with chemotherapy. The goal is to see which approach works better as a second-line treatment.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This trial tests a combination of drugs for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if this new mix can help control the cancer better.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Metastatic Colorectal Carcinoma (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.